SpringWorks Therapeutics Inc
NASDAQ:SWTX
Intrinsic Value
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. [ Read More ]
The intrinsic value of one
SWTX
stock under the Base Case scenario is
32.45
USD.
Compared to the current market price of 42.47 USD,
SpringWorks Therapeutics Inc
is
Overvalued by 24%.
SWTX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
SWTX or that its price is influenced by factors unrelated to fundamentals.
SpringWorks Therapeutics Inc's market capitalization is 3.1B USD.
SWTX stock price is 42.47 USD.
SWTX stock (32.45 USD) is 24% less than its price (42.47 USD).
SWTX. Open DCF Valuation
SWTX stock (32.45 USD) is 24% less than its price (42.47 USD). Open Relative Valuation
SWTX has upside potential of 60% compared to the average analyst price target.
Open Wall St Estimates
SWTX has positive Gross Profit for the last twelve months.
SWTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -14% to -55%, and is approaching profitability.
SWTX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -150% to -255%, and is approaching profitability.
SWTX has negative Operating Income for the last twelve months.
SWTX has negative Net Income for the last twelve months.
SWTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -55%.
SWTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -255%.
SWTX's Revenue is forecast to grow at a rate of 343% per year over the next 3 years.
SWTX has negative Free Cash Flow for the last twelve months.
SWTX's Revenue has been falling by 46% per year for the last 3 years.
SWTX has negative three-year average ROE (Return on Equity): -44%. The company is not efficient at transforming stockholders' equity into net income.
SWTX has negative three-year average ROIC (Return on Invested Capital): -455%. The company is not efficient at using invested capital to generate operating income.
SWTX's short-term assets (501m USD) exceed its short-term liabilties (78m USD).
SWTX's long-term assets (726m USD) exceed its long-term liabilties (100m USD).
SWTX's D/E (Debt to Equity) is very low and is equal to 0.
SWTX's Altman Z-Score is very high and is equal to 12.79.
Valuation Backtest
SpringWorks Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
SWTX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
SpringWorks Therapeutics Inc
Balance Sheet Decomposition
SpringWorks Therapeutics Inc
| Current Assets | 500.9m |
| Cash & Short-Term Investments | 479.2m |
| Receivables | 5.9m |
| Other Current Assets | 15.8m |
| Non-Current Assets | 224.9m |
| Long-Term Investments | 185.3m |
| PP&E | 24.1m |
| Intangibles | 11.2m |
| Other Non-Current Assets | 4.2m |
| Current Liabilities | 78.2m |
| Accounts Payable | 7.4m |
| Accrued Liabilities | 66.6m |
| Other Current Liabilities | 4.1m |
| Non-Current Liabilities | 21.4m |
| Other Non-Current Liabilities | 21.4m |
Earnings Waterfall
SpringWorks Therapeutics Inc
|
Revenue
|
5.4m
USD
|
|
Cost of Revenue
|
-422k
USD
|
|
Gross Profit
|
5m
USD
|
|
Operating Expenses
|
-348m
USD
|
|
Operating Income
|
-343m
USD
|
|
Other Expenses
|
17.9m
USD
|
|
Net Income
|
-325.1m
USD
|
Free Cash Flow Analysis
SpringWorks Therapeutics Inc
What is Free Cash Flow?
SWTX Profitability Score
Profitability Due Diligence
SpringWorks Therapeutics Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
SpringWorks Therapeutics Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
SWTX Solvency Score
Solvency Due Diligence
SpringWorks Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
SpringWorks Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SWTX Price Targets Summary
SpringWorks Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
SWTX
is 68.09 USD
with a low forecast of 58.58 USD and a high forecast of 84 USD.
Ownership
SWTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SWTX Price
SpringWorks Therapeutics Inc
| Average Annual Return | 21.64% |
| Standard Deviation of Annual Returns | 68.43% |
| Max Drawdown | -80% |
| Market Capitalization | 3.1B USD |
| Shares Outstanding | 74 059 904 |
| Percentage of Shares Shorted | 17.43% |
Company Profile
SpringWorks Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 176 full-time employees. The company went IPO on 2019-09-13. The firm is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.
Contact
IPO
Employees
Officers
The intrinsic value of one
SWTX
stock under the Base Case scenario is
32.45
USD.
Compared to the current market price of 42.47 USD,
SpringWorks Therapeutics Inc
is
Overvalued by 24%.
You don't have any saved screeners yet
